- Indication
- Asthma
- RAG rating
- Amber initiation
- Document type
- Decision document
- Place
- Hertfordshire and West Essex ICB
- Output type
- Pharmacy / Prescribing
Trimbow (ICS - beclometasone / LABA - formoterol / LAMA - glycopyrronium)
HERTFORDSHIRE AND WEST ESSEX AREA
PRESCRIBING COMMITTEE (HWE APC)
Trimbow® (ICS - beclometasone /
LABA - formoterol / LAMA - glycopyrronium)
pMDI (pressurized metered dose
inhaler) for treatment of asthma in adults
AMBER INITIATION
Recommended for initiation by specialists, ongoing
prescribing in primary care, following stabilisation of therapy, and after an
assessment of tolerability and efficacy has been made by the specialists.
|
Name generic (trade):
|
Beclometasone / formoterol / glycopyrronium
|
|
What it is:
|
Inhaled corticosteroid (ICS - beclometasone),
long-acting β2-agonist (LABA - formoterol) & long-acting muscarinic
antagonist (LAMA) - glycopyrronium) in a pMDI.
|
|
Indication:
|
For treatment of asthma in adults requiring ICS/LABA/LAMA who would benefit from a simplified treatment regime with a combination
triple therapy inhaler.
|
|
Date decision last revised:
|
September 2024
|
|
NICE
|
NICE NG245 recommended
|
HWE APC recommendation:
Trimbow®(ICS - beclometasone / LABA - formoterol / LAMA - glycopyrronium) pMDI for
treatment of asthma in adults (AMBER INITIATION status) - recommended for use
as option for maintenance treatment of asthma, not adequately controlled with a
combination of a LABA and ICS, and who experienced one or more asthma
exacerbations in the previous year, in patients who would benefit from a
simplified treatment regime with a combination triple therapy inhaler.
AMBER INITIATION:
At initiation, specialists must also counsel the patient on all aspects related to the safe and effective use of this medication.
Further information: for latest updates and more detailed
information, including contra-indications, cautions and special warnings; please
refer to summary of product characteristics SPC).
- Version number
- 1.0
- Developed by
- HWE ICB Pharmacy Medicines Optimisation Team
- Approved by
- HWE ICB Area Prescribing Committee
- Date approved / updated
- September 2024
- Review date
- The recommendation is based upon the evidence available at the time of publication. This recommendation will be reviewed upon request in the light of new evidence becoming available.
- Superseded version